Medtronic (NYSE:MDT) Canada announced that Health Canada licensed its Medtronic Extended infusion set for insulin pumps. The Medtronic Extended Infusion Set is the first and only infusion set labeled for a wear time of up to seven days. The infusion set for delivering insulin from a pump to the body typically requires changing every two […]
Medtronic
Medtronic launches 7-day infusion set for insulin pumps in U.S.
Medtronic (NYSE:MDT) announced today that it launched its Medtronic Extended Infusion set for seven-day wear with insulin delivery. The Medtronic Extended Infusion Set represents the first and only infusion set labeled for wearing of up to seven days. The infusion set for delivering insulin from a pump to the body typically requires changing every two […]
Health Canada licenses Medtronic next-gen MiniMed 780G insulin pump
Medtronic (NYSE:MDT) Canada announced today that Health Canada granted a license to its MiniMed 780G automated insulin delivery system. The company designed its MiniMed 780G advanced hybrid closed-loop insulin pump system to automatically adjust and correct sugars every five minutes. According to Medtronic, it marks the first and only insulin pump system in Canada to […]
Medtronic launches diabetes insights program for MiniMed users
Medtronic (NYSE:MDT) announced today that it introduced a new diabetes management program for users of the MiniMed 770G insulin pump. The medtech giant calls the new program My Insights. It designed it exclusively for individuals using the MiniMed 770G hybrid closed-loop insulin delivery system. Using an individual’s data, My Insight provides personalized tips, trends and […]
FDA approves Medtronic drug-eluting stents for treating bifurcation lesions
Medtronic (NYSE:MDT) announced today that the FDA approved its Onyx drug-eluting stents (DES) for treating certain lesions. Approval covers the treatment of non-left main bifurcation lesions utilizing the provisional bifurcation stenting technique. The technique uses a single stent to treat the bifurcation in percutaneous coronary interventions (PCIs). It applies to the FDA-approved and CE-marked Onyx […]
Medtronic, FDA warn on potential cybersecurity risk with MiniMed insulin pump
Medtronic (NYSE:MDT) issued an urgent medical device correction notice to warn of potential issues with some MiniMed automated insulin delivery systems. The notice — dated this month — covers the company’s MiniMed 600 series insulin pumps (MiniMed 630G and 670G). Affected devices also include the Guardian Link 3 transmitter, Contour Next Link 2.4 blood glucose […]
Investors sue Medtronic over insulin pump problems
Add a potential class action shareholder lawsuit to the challenges Medtronic (NYSE: MDT) is facing over its Diabetes business. The law firm of Kessler Topaz Meltzer & Check announced last week that it has sued the medtech giant in U.S. District in Minnesota, claiming securities fraud over how it disclosed insulin pump problems. The initial […]
Medtronic warns on Prevail Paclitaxel-coated PTCA balloon catheter
Medtronic this week issued an urgent field safety notice for some of its Prevail Paclitaxel-coated PTCA balloon catheters. The Fridley, Minnesota-based company issued the warning due to the potential for an incorrect compliance chart attached to the catheter hoop. The balloon size on the compliance chart differed from the balloon size detailed on the packaging, […]
Study backs next-gen Medtronic MiniMed 780G insulin pump
Medtronic (NYSE:MDT) today announced positive results from a study of its next-generation MiniMed 780G automated insulin delivery system. Results from the ADAPT study, published in The Lancet Diabetes & Endocrinology, demonstrated improved glycemic control and treatment satisfaction among users of MiniMed 780G. The MiniMed 780G system is available in more than 60 countries. It is currently […]
Medtronic launches Onyx Frontier drug-eluting stent
Medtronic (NYSE:MDT) launched its newest drug-eluting coronary stent, Onyx Frontier. The Fridley, Minnesota-based company designed the Onyx Frontier drug-eluting stent (DES) to build upon its Resolute Onyx DES. It uses the same stent platform as the Resolute Onyx and has an enhanced delivery system to increase acute performance in interventional coronary artery disease procedures. Get […]
